Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study
Authors' conclusion
We identified for the first time the mitochondrial-related biomarker IF1 as being associated with the risk of T2DM.
Study context
- Population
- Individuals with prediabetes, IT-DIAB prospective study
- Participants
- 307 individuals
- Exposure
- Plasma IF1 level and risk of new-onset diabetes
- Outcome
- Incidence of NOD
- Follow-up
- Within five years
Methodological detailscross-sectional analysis in two independent interventional studies
- Cross-sectional analysis in two independent interventional studies
Main finding
As reported in the abstract
Risk of T2DM per 1 SD plasma IF1, adjusted for age, sex and FPG
HR per 1 SD IF1 (95% CI 0.62; 0.94), P = 0.012
0.76
Observational data: associations, not effects.
Further findings
Mean baseline plasma IF1 · lower with NOD
P = 0.01
Correlations of plasma IF1 with metabolic parameters (Spearman) · baseline
- BMI, r (P = 0.0005)
- −0.20
- Homeostasis model assessment of insulin resistance (HOMA-IR), r (P < 0.0001)
- −0.37
- HDL-C, r (P < 0.0001)
- 0.63
- apoA-I, r (P < 0.0001)
- 0.33
- Correlations confirmed in cross-sectional analyses
Original publication
Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study. Diabetes Metab. Published 26 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →